Wall Street is positive on Can Fite Biopharma ADR Representing 30 Ord Shs (CANF). On average, analysts give the stock a Strong Buy rating. The average price target is $5, which means analysts expect the stock to increase by 222.58% over the next twelve months. That average ranking earns the stock an Analyst Rating of 75, which is better than 75% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating CANF a Strong Buy today. Find out what this means to you and get the rest of the rankings on CANF!